Study of PKI-179 Administered Orally to Subjects With Solid Tumors
Status:
Withdrawn
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This is an open label dose escalation study to find the maximum tolerated dose (MTD) of
PKI-179 in subjects with solid tumors. Part 1 of the study will be the dose estimation phase
and will be open to subjects with all solid tumors. Part 2 will be the dose confirmation
phase and will be open to subjects with breast, non small cell lung, ovarian, endometrial, or
colorectal cancer or glioblastoma. All subjects will receive daily oral dosing of PKI-179. A
continuous reassessment method (CRM) design will be used, which will take into account dose
limiting toxicity (DLT) information from each dose level explored in order to determine the
next dose level.